Why We Need a Federal Life Science Startup Package
When we look at Silicon Valley, it’s clear that new technology receives continuous support from many different directions to push it forward. Speed to market, significant funding sources and the public markets all contribute to innovation in technology. There’s also a pervasive sense of optimism, that the next big thing is right around the corner.
In life sciences, that same support does not exist. Instead of a forward push, life science experiences a constant pushback.
Venture capital money is difficult to find. There are slow lead times in getting new products to market. These factors and more clog the pipeline to bring new treatments to market, and public policy must find a way to create the tenuous balance between safety, innovation and scientific rigor.
Government can join with entrepreneurs to foster life science innovation through the creation of a Federal Life Science Startup Package.
Amy Millman has established a successful career as an advocate working for and with business and government officials to develop and implement national business development and policy initiatives. In 2000, she co-founded non-profit venture Springboard Enterprises whose mission is to facilitate women entrepreneurs' access to the equity markets. The organization hosts educational programs and forums to provide women entrepreneurs with access to investors and information about sources and uses of equity capital.
Previously, Amy served as the Executive Director of a federal government commission focused on developing policy and initiatives concerning women's business ownership. Earlier in her career, she represented the interests of several corporate and industry groups before the legislative and executive branches of the federal government. Amy has served on the boards of many organizations including her current service on the boards of JumpStartInc and Enterprising Women magazine. She is a graduate of Carnegie Mellon University and holds a masters degree from The George Washington University. She and her family reside in the Washington, D.C. area.
Founder & CEO
Dr. Joan Fallon is the founder and chief executive officer of Curemark LLC, a drug development and research company focused on the treatment of neurological diseases. Curemark reported positive FDA Phase III clinical trial results for CM-AT, a treatment for autism. Curemark was founded on Dr. Fallon’s research that revealed an enzyme deficiency in children with autism resulting in a dearth of amino acids, the building blocks of protein.
Dr. Fallon filed her first patent application in 1999 and has worked to research autism and related disorders, as well as to commercialize her findings. Her discovery of a biomarker for autism and ADHD and her vast array of intellectual property has formed the foundation of Curemark LLC. She presently holds 15 Patents, and has 42 patents pending worldwide.